Usage of the claim database of national health insurance programme for analysis of cisapride-erythromycin co-medication in Taiwan

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 1, 2007, Pages 86-95

  Gau, Churn Shiouh ^a   Chang, I Shou ^b   Wu, Fe Lin Lin ^a   Yu, Hui Tzu ^b   Huang, Yu Wen ^c   Chi, Cheng Liang ^b   Chien, Su Yu ^d   Lin, Keh Ming ^b   Liu, Ming Ying ^b   Wang, Hui Po ^e  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c DEPARTMENT OF HEALTH   (Taiwan)

^d CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^e CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Cisapride; Claim data; Co medication; Erythromycin; National Health Insurance Research Database

Indexed keywords

CISAPRIDE; ERYTHROMYCIN;

ACCREDITATION; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DATA BASE; DRUG EXPOSURE; DRUG INDICATION; DRUG SURVEILLANCE PROGRAM; FEMALE; HEART ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH INSURANCE; OUTPATIENT DEPARTMENT; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SAMPLE SIZE; TAIWAN; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CISAPRIDE; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ERYTHROMYCIN; GASTROINTESTINAL AGENTS; HEART DISEASES; HUMANS; INFANT; INSURANCE CLAIM REVIEW; INSURANCE, PHARMACEUTICAL SERVICES; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PHYSICIAN'S PRACTICE PATTERNS; PNEUMONIA; PRESCRIPTIONS, DRUG; PRODUCT SURVEILLANCE, POSTMARKETING; RISK ASSESSMENT; TAIWAN;

EID: 33846555629     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1324     Document Type: Article

References (34)

1. Wiseman LR, Faulds D. Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994; 47: 116-152.
2. Cucchiara S. Cisapride therapy for gastrointestinal disease. J Pediatr Gastroenterol Nutr 1996; 22: 259-269.
3. DeVault KR, Castell DO. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Practice Parameters Committee of the American College of Gastroenterology. Arch Intern Med 1995; 155: 2165-2173.
4. Vandenplas Y, Belli DC, Benatar A, et al. The role of cisapride in the treatment of pediatric gastroesophageal reflux. The European society of paediatric gastroenterology, hepatology and nutrition. J Pediatr Gastroenterol Nutr 1999; 28: 518-528.
5. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996; 335: 290-291.
6. Gheuens J. Janssen Pharmaceutica. Letter Propulsid Tablets and Suspension (cisapride) 2000. Available from URL: http://www.fda.gov/ medwatch/safety/2000/propull.htm/. [Accessed 2004 Sept.]
7. Wysowski DK, Corken A, Gallo-Torres H, Talarico L, Rodriguez EM. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001; 96: 1698-1703.
8. Michalets EL, Williams CR. Drug interactions with cisapride: clinical implications. Clin Pharmacokinet 2000; 39: 49-75.
9. Shulman RJ, Boyle JT, Colletti RB, et al. An updated medical position statement of the North American society for pediatric gastroenterology and nutrition. J Pediatr Gastroenterol Nutr 2000; 31: 232-233.
10. Shulman RJ, Boyle JT, Colletti RB, et al. The use of cisapride in children. The North American society for pediatric gastroenterology and nutrition. J Pediatr Gastroenterol Nutr 1999; 28: 529-533.
11. McCallum RW, Prakash C, Campoli-Richards DM, Goa KL. Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders. Drugs 1988; 36: 652-681.
12. Breckenridge A. Suspension of cisapride (Prepulsid) licenses: product Withdrawal. Committee on Safety of Medicines, London 2000.
13. Henny J. Withdrawal of troglitazone and cisapride. JAMA 2000; 283: 2228.
14. Department of Statistics, Ministry of the Interior. Available from URL: http://www.moi.gov.tw/stat/index.asp. [Accessed 2004 Dec.]
15. Bureau of National Health Insurance. National Health Insurance Annual Statistical Report, 2003. Bureau of National Health Insurance: Taiwan; 2003.
16. Bureau of Pharmaceutical Affairs, Department of Health of Taiwan. Labeling change in contraindication, warning, precaution and dosage of cisapride products. 1999; Number 88055919. Available from URL: http://www.doh.gov.tw/NewVersion/content.asp?class_no= 79&now_Fod_lisst=2564&array_Fod_list_no= 79,2553&level=2&doc_no=10759. [Accessed 2004 Dec.]
17. Bureau of Pharmaceutical Affairs, Department of Health of Taiwan. Withdraw of cisapride products. June, 2004; Number 0930316562. Available from URL: http://www.doh.gov.tw/ufile/200408 [Accessed 2006 Mar.]
18. Otterson MF, Sarna SK. Gastrointestinal motor effects of erythromycin. Am J Physiol 1990; 259: 355-363.
19. Peeters T, Matthijs G, Depoortere I, Cachet T, Hoogmartens J, Vantrappen G. Erythromycin is a motilin receptor agonist. Am J Physiol 1989; 257: 470-474.
20. Jenkins IR, Gibson J. Cisapride, erythromycin and arrhythmia. Anaesth Intensive Care 1996; 24: 728.
21. Shulman RJ. Report from the NASPGN Therapeutics Subcommittee. Cisapride and the attack of the P-450s. J Pediatr Gastroenterol Nutr 1996; 23: 395-397.
22. National Health Insurance Research Databases. Available from URL: http://www.nhri.org.tw/nhird/date_cohort.htm. [Accessed 2004 Dec.]
23. Taiwan Joint Commission on Hospital Accreditation. Available from URL: http://www.tjcha.org.tw/inspect/inspect.asp/. [Accessed 2004 Dec.]
24. National Health Insurance Research Databases. Available from URL: http://www.nhri.org.tw/nhird/date_01.htm. [Accessed 2006 Mar.]
25. Chien IC, Chow YJ, Lin CH, Bih SH, Chou P. Prevalence of psychiatric disorders among national health insurance enrollees in Taiwan. Psychiatric Services 2004; 55: 691-697.
26. Product Information: Propulsid (R), cisapride. Janssen Pharmaceutics Inc., Titusville, NJ, (PI revised 1/00) reviewed 1/2000.
27. Drug Facts and Comparisons Publishing Groups. Drugs Facts and Comparisons 1999. Drug Facts and Comparisons: St. Louis; 1999: 2116-2119.
28. National Taiwan University Hospital growth nomogram of children. Available from URL: http://med.mc.ntu.edu.tw/~ped/health/he10/ he10-4.htm/. [Accessed 2004 Dec.]
29. Khoshoo V, Edell D, Clarke R. Effect of cisapride on the QT interval in infants with gastroesophageal reflux. Pediatrics 2000; 105: E24.
30. American Society of Health-System Pharmacists. AHFS drug information 1999. American Society of Health-System Pharmacists, Inc.: Bethesda; 1999: 2559-2562.
31. Health and National Health Insurance Annual Statistics Information Services. Available from URL: http://www.doh.gov.tw/statistic/index.htm. [Accessed 2005 Mar.]
32. Bureau of National Health Insurance. Available from URL: http://www.nhi.gov.tw/12lawrule/index_lawrule.htm. [Accessed 2004 Dec.]
33. Verheyen K, Vervaeke M, Kemyttenaere P. Double-blind comparison of two cisapride dosage regimens with placebo in the treatment of functional constipation: a general proactive multicenter study. Curr Ther Res 1987; 41: 978-985.
34. Walker AM, Szneke P, Weatherby LB, et al. The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada. Am J Med 1999; 107: 356-362.